These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 38741354

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia.
    Marvin-Peek J, Jen WY, Kantarjian HM, McCue D, Haddad FG, Wierda W, Ferrajoli A, Burger J, Abusab T, Jorgensen J, Wang SA, Patel K, Loghavi S, O'Brien S, Ravandi F.
    Leuk Lymphoma; 2024 Sep; 65(9):1325-1334. PubMed ID: 38749022
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia.
    Ravandi F, O'Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, Koller C, Challagundla P, York S, Brandt M, Luthra R, Burger J, Thomas D, Keating M, Kantarjian H.
    Blood; 2011 Oct 06; 118(14):3818-23. PubMed ID: 21821712
    [Abstract] [Full Text] [Related]

  • 11. Inhibitor of BRAFV600E Mutation as a Treatment Option for Hairy Cell Leukemia With Deep Neutropenia and Infectious Complications.
    Smirnova SY, Al-Radi LS, Moiseeva TN, Gemdzhian EG, Yakutik IA, Julhakyan HL, Novikov VA, Galstyan GM, Sudarikov AB.
    Clin Lymphoma Myeloma Leuk; 2021 Jul 06; 21(7):427-430. PubMed ID: 33811006
    [Abstract] [Full Text] [Related]

  • 12. The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience.
    Broccoli A, Argnani L, Nanni L, Terragna C, Sabattini E, Gabrielli G, Stefoni V, Pellegrini C, Casadei B, Morigi A, Lolli G, Carella M, Coppola PE, Zinzani PL.
    Am J Hematol; 2021 Oct 01; 96(10):1204-1210. PubMed ID: 34245477
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population.
    Madanat YF, Rybicki L, Radivoyevitch T, Jagadeesh D, Dean R, Pohlman B, Kalaycio M, Sekeres MA, Smith MR, Hill BT.
    Clin Lymphoma Myeloma Leuk; 2017 Dec 01; 17(12):857-862. PubMed ID: 28778620
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Molecular variant of hairy cell leukemia with poor prognosis.
    Arons E, Kreitman RJ.
    Leuk Lymphoma; 2011 Jun 01; 52 Suppl 2(Suppl 2):99-102. PubMed ID: 21599610
    [Abstract] [Full Text] [Related]

  • 17. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine.
    Goodman GR, Burian C, Koziol JA, Saven A.
    J Clin Oncol; 2003 Mar 01; 21(5):891-6. PubMed ID: 12610190
    [Abstract] [Full Text] [Related]

  • 18. Update on the biology and treatment options for hairy cell leukemia.
    Jain P, Pemmaraju N, Ravandi F.
    Curr Treat Options Oncol; 2014 Jun 01; 15(2):187-209. PubMed ID: 24652320
    [Abstract] [Full Text] [Related]

  • 19. [Clinical analysis of 24 patients of hairy cell leukemia treated by cladribine].
    Wang TY, Li ZJ, Lyu R, Fu MW, Sui WW, Huang WY, Liu W, An G, Deng SH, Qiu LG.
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jun 14; 39(6):491-495. PubMed ID: 30032567
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.